MARCH 27
Days
- :
Hrs
- :
Min
- :
Sec
ePoster Gallery
P368: Lipid Rafts Modulate c-Myc Phosphorylation in Pancreatic Cancer In Vitro
Jakob Hamilton M.S., B.S., B.A.
University of Florida College of Medicine
P369: Liver Metastasectomy in Ovarian Cancer: Is There a Survival Benefit?
Lauren Springsteen
Medical College of Georgia, Augusta University
P371: Mapping Multimorbidity Trajectories for Pancreas Cancer from Real World Data
Adriana Gamboa MD
MD Anderson Cancer Center
P372: Modulation of RBP-1 Phosphorylation is a Novel Therapeutic Vulnerability in Fibrolamellar Carcinoma
Patrick Carney MD, PhD
University of Wisconsin-Madison
P373: National Assessment of Pathologic Complete Response to Modern Neoadjuvant Therapy Regimens in Pancreatic Ductal Adenocarcinoma
Szu-Aun Long MD
University of Cincinnati Medical Center
P374: National Assessment of Systemic Therapy Approaches for Intrahepatic Cholangiocarcinoma
Catherine Pratt MD, MS
University of Cincinnati College of Medicine
P377: Pancreatic fistula after distal pancreatectomy: an updated global evaluation of rates and risk factors
Liti Zhang MD
Cedars-Sinai Medical Center
P379: Pharmacodynamics of intra-arterial vs. intravenous gemcitabine in locally advanced pancreatic cancer: results of a phase III randomized clinical trial
Emmanuel Zervos
P380: Practice Patterns and Outcomes for Perioperative Systemic Therapy for Biliary Tract Malignancies in the Post-BILCAP Era: A National Cancer Database Analysis
Thomas Sutton MD MCR
Cedars-Sinai Medical Center
P381: Predictors and Outcomes of Conversion from Robotic to Open Pancreatoduodenectomy: A Large Multicenter Analysis
Ricardo E. Nunez-Rocha Postdoctoral Research Fellow
University of Texas Southwestern Medical Center
P382: Preoperative nomogram based on DUPAN-2, tumor size, and neutrophil/lymphocyte ratio (DIZNEY score) for deciding the appropriate time of radical resection for pancreatic cancer
Hiromitsu Maehira
Department of Surgery, Shiga University of Medical Science
P383: Prognostic Nomogram for CA19-9 Non-Secretors with Resected Pancreatic Ductal Adenocarcinoma
Jurgis Alvikas
University of Pittsburgh Medical Center
P384: Prognostic Value of Preoperative CA19-9 in Patients with Pancreatic Cancer
Pratik Chandra MD
Memorial Sloan Kettering Cancer Center
P385: Recurrence Patterns for Pancreatic Adenocarcinoma Treated with Upfront Surgical Resection Versus a Neoadjuvant Approach: A Systematic Review and Meta-analysis
Akie Watanabe
University of British Columbia
P386: Response After Neoadjuvant Therapy for Pancreatic Neuroendocrine Tumors
Makayla Slaby
P387: Surgical referrals for colorectal liver metastases: Assessing patterns and outcomes at a high-volume, safety-net hospital
Morgan Pettigrew MD
UT Southwestern Medical Center
P388: Survival of pancreatic mucinous adenocarcinoma versus pancreatic ductal adenocarcinoma: A 10-year propensity score-matched analysis
Hadley Freeman MD
Loma Linda University Health
P389: TNIK Inhibition Increases Invasiveness in Classical Subtype Pancreatic Adenocarcinoma
Hannah Trembath M.D., M.S.
University of North Carolina at Chapel Hill